The aim of this work was to assess the cost-effectiveness of induction and maintenance treatment of UC with following biologic drugs: infliximab, adalimumab, and golimumab, in Poland. Study population consists of patients with moderate to severe UC, who failed standard treatment or when it was not tolerated or contraindicated. Biologic drugs were administrated with standard care and were compared with standard care alone. To assess the long-term costs and effects of compared interventions, Markov model was used. Due to the influence of treatment on life years and life quality of patients from analised population, cost-utility analysis was conducted. Analysis were conducted from public payer’s perspective and additionally from social perspective in case of adalimumab and golimumab, in life-long time horizon. Biologic treatment with standard care compared with standard care alone resulted in quality adjusted life years gained equaled from 0,11 to 0,14 and was more expensive from public payer’s perspective and from social perspective. Incremental cost-effectiveness ratio was from 320 thous. PLN/QALYG (adalimumab) to 402 thous. PLN/QALYG (infliximab without restriction for treatment duration) from public payer’s perspective and from 300 thous. PLN/QALYG (adalimumab) to 374 thous. PLN/QALYG (golimumab) from social perspective. Incremental cost-effectiveness ratios exceeded the threshold value in Poland
Oct 24, 2017
Oct 17, 2017
|ZB-126656||Oct 24, 2017|
Mrożek-Gąsiorowska, Magdalena A.